Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Glaxosmithkline Corporate Intellectual Property _ Uw2220 patentsThe following is a sampling of recent Glaxosmithkline Corporate Intellectual Property _ Uw2220 patent applications (USPTO Patent Application #, Patent Title) sorted by month.
July 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090176746 - Thrombopoietin mimetics 20090170066 - Methods and materials therefor June 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090156597 - Novel compounds 20090148437 - Polypeptides, antibody variable domains & antagonists 20090143372 - Chemical compounds 20090143453 - Methods for treating degenerative diseases/injuries May 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090130126 - Dna expression vectors 20090123496 - Purification of hbv antigens for use in vaccines 20090118280 - Compounds which potentiate ampa receptor and uses thereof in medicine April 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090104229 - Novel use 20090104229 - Novel use 20090104229 - Novel use 20090105478 - Novel compounds 20090105478 - Novel compounds 20090105478 - Novel compounds 20090093478 - N-aroyl cyclic amines March 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090082377 - Matrix metalloproteinase inhibitors 20090082390 - Piperidine compounds for use as orexin receptor antagonist 20090076274 - Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders February 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090053214 - Humanised anti-mag antibody or functional fragment thereof 20090053291 - Fusion proteins comprising hiv-1 tat and/or nef proteins 20090048318 - Methods for treating degenerative diseases/injuries 20090048442 - Novel compounds 20090048444 - Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives January 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090029986 - N-aroyl cyclic amines 20090022670 - Novel compounds 20090017020 - Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders 20090018131 - Quinazoline derivatives as p13 kinase inhibitors 20090012073 - N-aroyl cyclic amines 20090012099 - Novel compounds 20090012122 - N-aroyl cyclic amine derivatives as orexin receptor antagonists 20090005401 - Novel compounds October 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080260781 - Proteosome influenza vaccine 20080262069 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment 20080255115 - Thiazolidinedione derivatives as pi3 kinase inhibitors September 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080227858 - Inhibitors of matrix metalloproteinase 20080221110 - Compounds 20080213212 - Sialoadhesin factor-2 antibodies 20080214640 - Thrombopoietin mimetics August 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080206189 - Method of treating cancer by administering conjugates comprising human il-18 and substitution mutants thereof 20080199494 - Vaccine 20080194648 - Compounds which potentiate glutamate receptor and uses thereof in medicine 20080188469 - Vaccination July 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080181914 - Novel vaccine composition 20080182852 - Anthranilamide inhibitors of aurora kinase 20080176245 - Detection of viable agents June 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080152671 - Novel vaccination 20080131464 - Vaccines May 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080118527 - Novel composition 20080114010 - Novel substituted imidazole compounds 20080114049 - Chemical compounds 20080108615 - Imidazole-2-carboxamide derivatives as raf kinase inhibitors 20080102085 - Vaccine comprising gp120 and nef and/or tat for the immunization against hiv 20080102112 - Chlamydia vaccines April 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080095854 - Dna dosage forms 20080096951 - Carvedilol monocitrate monohydrate 20080089902 - Fusion proteins comprising hiv-1 tat and/or nef proteins 20080089929 - Fusion proteins comprising hiv-1 tat and/or nef proteins 20080090787 - Thrombopoietin mimetics 20080090853 - Bicyclic heteroaromatic compounds 20080090881 - Treatment of diabetes with thiazolidinedione and metformin 20080090996 - Thrombopoietin mimetics 20080081050 - Vaccine against streptococcus pneumoniae 20080081808 - Azaindole inhibitors of aurora kinases March 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080072992 - Novel process 20080076672 - Methods for identifying genes essential to the growth of an organism 20080076763 - Inhibitors of akt activity 20080070973 - Compounds having activity at the glyt1 transporter 20080063662 - Vaccine 20080057082 - Vaccine 20080058369 - Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors 20080058378 - Compounds which have activity at m1 receptor and their uses in medicine. 20080058388 - Treatment of diabetes with thiazolidinedione and sulphonylurea 20080058398 - Compounds February 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080044409 - Inflammatory mediator antagonists January 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080025993 - Method for refolding neisserial nspa protein 20080019967 - Inflammatory mediator antagonists 20080021023 - Morpholinyl and pyrrolidinyl analogs 20080014195 - Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases 20080014266 - Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent 20080004308 - Azaindole inhibitors of aurora kinases December 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070298470 - Isolated dna comprising one or more genes specific for 5s clavam biosynthesis, vectors comprising such dna and streptomyces hosts capable of improved clavulanic acid production 20070281023 - Pharmaceutical composition for modified release insulin sensitiser 20070281977 - Novel heterocyclic compounds November 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070274929 - Oral composition comprising chlorhexidine and maltitol or erythritol or a mixture thereof 20070275054 - Novel composition and use 20070275063 - Sustained release pharmaceutical compositions and methods of treatment using the same 20070275979 - Novel compounds 20070269451 - Nucleic acid vaccination 20070270456 - M3 muscarinic acetylcholine receptor antagonists 20070264258 - Sialoadhesin factor-2 antibodies 20070264283 - Vaccine 20070259882 - 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists 20070259940 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment October 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070248679 - Vaccine 20070248997 - Method of using one-dimensional and multi-dimensional nuclear magnetic resonance to identify compounds that interact with target biomolecules 20070249664 - Muscarinic acetylcholine receptor antagonists 20070244123 - Heterocycle-carboxamide derivatives as raf kinase inhibitors 20070244150 - Muscarinic acetylcholine receptor antagonists 20070237788 - Non-live trivalent influenza vaccine for one-dose intradermal delivery 20070238151 - Novel compounds 20070238743 - 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases 20070238757 - Novel treatment 20070232808 - Process for preparing heterocyclic derivatives September 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070224198 - Antithrombotic agents 20070219232 - Chemical compounds August 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070203200 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical 20070196394 - Immunogenic compositions comprising liver stage malarial antigens 20070190578 - Method of site specific labeling of proteins and uses therefor 20070191435 - Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione 20070179144 - 5(z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one July 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070167423 - Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors 20070167467 - 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases 20070161083 - Codon optimized recombinant dermaphagoides allergens 20070161560 - Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain 20070151058 - Toothbrush 20070155762 - 5,6-trimethylenepyrimidin-4-one compounds 20070155792 - Peptide deformylase inhibitors 20070155810 - Peptide deformylase inhibitors June 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070148995 - System for providing communication between the interior and the exterior of a compartment 20070149505 - Method of inhibiting adhesion formation 20070142451 - Carvedilol hydrobromide 20070135422 - Nitrogen-containing bicycle heterocycles for use as antibacterials 20070135433 - Imidazole derivatives as raf kinase inhibitors 20070129415 - Method of treating isolated systolic hypertension May 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070122423 - Derp1 and proderp1 allergen derivatives 20070123549 - Pyrimidine compounds 20070112046 - 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors 20070104784 - Compositions and methods of treatment comprising amoxicillin and potassium clavulante with xanthan 20070105860 - Biphenylcarboxylic amide derivatives as p38 kinase inhibitors April 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070087049 - Multi-component pharmaceutical dosage form 20070088064 - Pharmaceutical composition containing bicyclic type compounds February 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070037859 - Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use 20070031368 - Chemokine conjugates January 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070020288 - Vaccine 20070021348 - Novel treatment 20070015769 - Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions 20070004780 - Treatment of diabetes with thiazolidinedione and metformin December 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060288510 - Toothbrush 20060292170 - Vaccine composition against malaria 20060292648 - Method of screening for inhibitors of osteopontin 20060280756 - Novel composition November 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060269539 - Asp2 20060263852 - Asp2 20060263853 - Recombinant il4 antibodies useful in treatment of il4 mediated disorders 20060257418 - Vaccine 20060258687 - Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives 20060251671 - Haemophilus influenza outer membrane protein and use thereof in vaccination 20060252799 - Benzo (f) insoindol derivatives and their use as ep4 receptor ligands 20060247279 - Thiazolidinedione derivative and its use as antidiabetic October 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060240505 - Identification of targets of antimicrobial compounds 20060235026 - Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists 20060235029 - Novel compounds 20060235030 - Novel compounds 20060223082 - Map 20060223819 - Quinoline derivatives as nk-3 antagonists September 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060204520 - Vaccine composition 20060205641 - Vanilrep4 polypeptides and vanilrep4 polynucleotides
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Corporate Intellectual Property _ Uw2220 in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Corporate Intellectual Property _ Uw2220 with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support
|